Avalo Therapeutics Inc Net Assets
Avalo Therapeutics Inc net assets. Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has net assets worth $91.55 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($125.10 Million) and total liabilities ($33.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Avalo Therapeutics Inc (AVTX) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $91.55 Million |
| % of Total Assets | 73.18% |
| Annual Growth Rate | 25.79% |
| 5-Year Change | 441.62% |
| 10-Year Change | 916.75% |
| Growth Volatility | 4191.97 |
Net Assets of Avalo Therapeutics Inc (2012–2024)
Net assets of Avalo Therapeutics Inc from 2012 to 2024. This chart illustrates how Avalo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See AVTX net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Avalo Therapeutics Inc from 2012 to 2024. For live market cap and overall valuation, see AVTX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $133.03 Million | +1721.36% |
| 2023-12-31 | $7.30 Million | +166.92% |
| 2022-12-31 | $-10.91 Million | -147.29% |
| 2021-12-31 | $23.08 Million | -6.03% |
| 2020-12-31 | $24.56 Million | +16.99% |
| 2019-12-31 | $21.00 Million | +0.42% |
| 2018-12-31 | $20.91 Million | -24.95% |
| 2017-12-31 | $27.86 Million | +13358.75% |
| 2016-12-31 | $207.00K | -98.42% |
| 2015-12-31 | $13.08 Million | +149.69% |
| 2014-12-31 | $-26.33 Million | -47.54% |
| 2013-12-31 | $-17.85 Million | -310.56% |
| 2012-12-31 | $8.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avalo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35629022200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Avalo Therapeutics Inc Net Assets Breakdown (December 2024)
Avalo Therapeutics Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.01% |
| Other Components | $503.29 Million | 378.32% |
| Total Equity | $133.03 Million | 100.00% |
Avalo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Avalo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acusensus Ltd
AU:ACE
|
$134.24 Million |
|
DEEZER S.A. EO 1
F:L0A
|
$134.28 Million |
|
Hyundai Pharm
KO:004310
|
$134.30 Million |
|
Hawesko Holding AG
XETRA:HAW
|
$134.30 Million |
|
Blue Water Acquisition Corp. IV
NYSE:BWIV
|
$134.12 Million |
|
Dynacons Systems & Solutions Limited
NSE:DSSL
|
$134.09 Million |
|
Ekovest Bhd
KLSE:8877
|
$134.01 Million |
|
Baiksan
KO:035150
|
$133.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avalo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,304,000 to 133,032,000, a change of 125,728,000 (1721.4%).
- Net loss of 35,129,000 reduced equity.
- Share repurchases of 68,000 reduced equity.
- New share issuances of 115,625,000 increased equity.
- Other factors increased equity by 45,300,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.13 Million | -26.41% |
| Share Repurchases | $68.00K | -0.05% |
| Share Issuances | $115.62 Million | +86.92% |
| Other Changes | $45.30 Million | +34.05% |
| Total Change | $- | 1721.36% |
Book Value vs Market Value Analysis
This analysis compares Avalo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $161.42 | $7.25 | x |
| 2013-12-31 | $-58.99 | $7.25 | x |
| 2014-12-31 | $-68.24 | $7.25 | x |
| 2015-12-31 | $16928.01 | $7.25 | x |
| 2016-12-31 | $67.51 | $7.25 | x |
| 2017-12-31 | $4278.14 | $7.25 | x |
| 2018-12-31 | $1731.63 | $7.25 | x |
| 2019-12-31 | $1057.76 | $7.25 | x |
| 2020-12-31 | $962.80 | $7.25 | x |
| 2021-12-31 | $637.78 | $7.25 | x |
| 2022-12-31 | $-278.43 | $7.25 | x |
| 2023-12-31 | $26.30 | $7.25 | x |
| 2024-12-31 | $12.34 | $7.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avalo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7965.76%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-26.41%) is above the historical average (-728.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -123.76% | -12674.72% | 0.01x | 1.18x | $-11.34 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.26 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.42 Million |
| 2015 | -80.17% | 0.00% | 0.00x | 1.66x | $-11.80 Million |
| 2016 | -7957.00% | -1428.53% | 0.20x | 27.87x | $-16.49 Million |
| 2017 | 42.61% | 42.68% | 0.64x | 1.55x | $9.08 Million |
| 2018 | -191.57% | -218.55% | 0.26x | 3.36x | $-42.14 Million |
| 2019 | -76.55% | -238.10% | 0.19x | 1.72x | $-18.17 Million |
| 2020 | -258.53% | -947.90% | 0.15x | 1.78x | $-65.96 Million |
| 2021 | -365.55% | -1563.10% | 0.07x | 3.48x | $-86.68 Million |
| 2022 | 0.00% | -230.78% | 0.54x | 0.00x | $-40.57 Million |
| 2023 | -431.87% | -1639.50% | 0.09x | 2.87x | $-32.27 Million |
| 2024 | -26.41% | -7965.76% | 0.00x | 1.13x | $-48.43 Million |
Industry Comparison
This section compares Avalo Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avalo Therapeutics Inc (AVTX) | $91.55 Million | -123.76% | 0.37x | $134.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more